Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, ...

EMA launched its adaptive pathways pilot in 2014 to speed access to new medicines in areas of "high medical need" by leveraging existing approval pathways to support "early and progressive patient ...

In the last three months, 4 analysts have published ratings on Adaptive Biotechnologies (NASDAQ:ADPT), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.22 per share a year ago. These ...

Pharmaceutical companies and EU industry groups pushed back against the expectation for sponsors to justify their choice to use adaptive clinical trial designs in the International Council on ...